InvestorsHub Logo
Followers 74
Posts 15841
Boards Moderated 0
Alias Born 04/26/2010

Re: studythosestocks post# 368803

Friday, 02/04/2022 2:50:33 PM

Friday, February 04, 2022 2:50:33 PM

Post# of 425976

Therefore, it would be appropriate for the company to only provide additional analyses and information for the secondary prevention subgroup

.

WTF? Shouldn't that have been the main info provided, since secondary prevention was a PE and primary prevention was an SE? How could AMRN NOT have provided them this info?

The committee concluded that given the uncertainty and the company’s base case ICERs, icosapent ethyl could not be recommended for any of the populations considered."



Costs too much money even in the secondary prevention group, but they claim they don't have enough info to evaluate it for that use? Who the hell are these people - and why is their ICER analysis so far off from the US's, $20k/QYLD vs $50k?

The Thought Police: To censor and protect. Craig Bruce

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News